I like management's approach. OIC could be a huge driver of revenue because, and I don't mean to be so dower, but we all kick the bucket and most of us will be on opiods for pain at some point and a huge percentage will develop constipation as a result. But even more, I like cobiprostone for oral mucositis. The only other treatment for this is some quackery called Mugard. Cobiprostone could be a huge revenue generator. I am embarrassed to say that I wanted to buy at $6.7 but didn't pull the trigger. Now, I have been given another chance to buy near that point, just above $7. Woohoo
I'd been picking up small chunks over the last week or so. Upon looking at my statement summary, I discovered I have A LOT. During this time I also had surgery and had to take morphine sulphate and dang if I wasn't constipated for about 3 days. It's the kind of coincidence that I wouldn't describe as serendipity.
you almost sound like an employee of sucampo Mr football. Can you come up with some argument why it is down when lot of other biotechs are up?? I am holding but it doesn't give me enough reason to buy in more. the volume is generally low but trade is trending lower so we have to wait for some good news before it can more back to atleast the $7s.